Abstract | OBJECTIVES: DESIGN: Retrospective single-centre consecutive series. MATERIALS AND METHODS: RESULTS: A total of 24 patients between 7 and 78 years were treated (19 venous malformations, three KTSs and two venous-lymphatic malformations). The concentrations of polidocanol used ranged from 0.25% to 3%. The average number of sessions was 2.3 (1-16). After a median follow-up at 5 months after the last session, 23 out of 24 patients reported a decrease in pain; in nine cases (37.5%), over 50% reduction in size was observed, and in 14 cases (58.3%), a reduction of less than 50% of the original size was obtained. Two minor side effects were reported. CONCLUSIONS:
|
Authors | S Blaise, M Charavin-Cocuzza, H Riom, M Brix, C Seinturier, J M Diamand, G Gachet, P H Carpentier |
Journal | European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery
(Eur J Vasc Endovasc Surg)
Vol. 41
Issue 3
Pg. 412-7
(Mar 2011)
ISSN: 1532-2165 [Electronic] England |
PMID | 21111641
(Publication Type: Journal Article, Review)
|
Copyright | Copyright © 2010 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved. |
Chemical References |
- Sclerosing Solutions
- Polidocanol
- Polyethylene Glycols
|
Topics |
- Adolescent
- Adult
- Aged
- Child
- Female
- France
- Humans
- Male
- Middle Aged
- Polidocanol
- Polyethylene Glycols
(administration & dosage, adverse effects)
- Regional Blood Flow
- Retrospective Studies
- Sclerosing Solutions
(administration & dosage, adverse effects)
- Sclerotherapy
(adverse effects)
- Time Factors
- Treatment Outcome
- Ultrasonography, Interventional
- Vascular Malformations
(diagnostic imaging, physiopathology, therapy)
- Young Adult
|